NewYork-Presbyterian Establishes William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma


Get Permission

NewYork-Presbyterian has established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma. Launched with an initial $5 million gift from William Rhodes, the new state-of-the-art program conducts groundbreaking research and provides cutting-edge treatments for glioblastoma and other deadly brain cancers. Mr. Rhodes, who has been a Life Trustee of -NewYork-Presbyterian since 1992, is also issuing a challenge grant program to accelerate fundraising for the new center.

The William Rhodes and Louise -Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian aims to advance care for glioblastoma and other brain cancers via a three-pronged approach: providing multidisciplinary, research-driven patient care, with a focus on genomic and precision medicine; emphasizing translational research to rapidly bring promising new therapies from the bench to the bedside; and educating the next generation of clinicians and scientists, with new fellowships created to expose young physicians to the most cutting-edge work being done in the field.

Center Leadership

The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma is led by four renowned experts in neuro-oncology:

  • Jeffrey Bruce, MD, FACS, Co-Director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center; Neuro-Oncology Program Leader in the Herbert Irving Comprehensive Cancer Center; Director of the Bartoli Brain Tumor Research Laboratory; and the Edgar M. Housepian Professor of Neurological Surgery Research at Columbia University Medical Center
  • Andrew Lassman, MD, Chief of the Division of Neuro-Oncology in the Department of Neurology and Co-Director of the Brain Tumor Center at NewYork-Presbyterian/Columbia University Medical Center; Medical Director for the Clinical Protocol Data Management Office of the Herbert Irving Comprehensive Cancer Center; and the John Harris Associate Professor of Neurology at Columbia University Medical Center
  • Howard Fine, MD, Founding Director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, who was recruited as the Louis and Gertrude Feil Professor of Medicine and Associate Director for Translational Research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
  • Rohan Ramakrishna, MD, Surgical Neuro-Oncologist in the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine and the Alvina and Willis Murphy Assistant Professor of Neurological Surgery at Weill Cornell Medicine. ■


Advertisement

Advertisement



Advertisement